RESUMO
Several studies indicated the ameliorating effects of flaxseed supplementation on apolipoproteins, although others have conflicting results. Therefore, the present research was conducted in order to accurately and definitively understand the effect of flaxseed on apolipoproteins in adults. All articles published up to Juan 2024 were systematically searched through PubMed, Scopus, Embase, and Web of Science to collect all randomized clinical trials (RCTs). A random effects model was used to measure the combined effect sizes. Also, standardized mean difference (SMD) and 95â¯% confidence interval (CI) were used to report the combined effect size. Our results showed that flaxseed supplementation significantly reduced apo-BI (SMD: -0.57; 95â¯% CI: -0.95, -0.19, p = 0.003; I2 = 83.2â¯%, heterogeneity p < 0.001) and lipo(a) decreased (SMD: -0.34; 95â¯% CI: -0.59, -0.09, p=0.007; I2=30.3â¯%, heterogeneity p=0.197). However, flaxseed did not change apo-AI levels (SMD: -0.37; 95â¯% CI: -0.87, 0.13, p = 0.146; I2 = 89.2â¯%, p-heterogeneity < 0.001). This meta-analysis has shown that flaxseed supplementation may have beneficial effects on apolipoproteins. Future high-quality, long-term clinical trials are needed to confirm our results.
RESUMO
BACKGROUND AND AIM: Several experiments have suggested that Nigella sativa (N. sativa) supplementation may have a beneficial effect on the lipid profile. However, the results from these trials have been inconclusive. Therefore, this study aimed to explore the impact of N. sativa supplementation on the lipid profile of adult participants. METHODS: We searched Scopus, Web of Science, PubMed, Cochrane, and Web of Science databases until December 2022. Random effects models were used, and pooled data were determined as standardized mean differences with a 95% confidence interval. RESULTS: The findings of 34 studies with 2278 participants revealed that N. sativa supplementation significantly reduced total cholesterol (TC) (SMD: -1.78; 95% CI: -2.20, -1.37, p < 0.001), triglycerides (TG) (SMD: -1.2725; 95% CI: -1.67, -0.83, p < 0.001), and low-density lipoprotein cholesterol (LDL-C) (SMD: -2.45; 95% CI: -3.06, -1.85; p < 0.001) compared to control groups. However, a significant increase was found in high-density lipoprotein cholesterol (HDL-C) (SMD: 0.79; 95% CI: 0.38, 1.20, p < 0.001). CONCLUSION: N. sativa has improved effects on TG, LDL-C, TC, and HDL-C levels. Overall, N. sativa may be suggested as an adjuvant anti-hyperlipidemic agent.